Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has announced they plan to collaborate with Enterin, which is a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to its key intermediates and active pharmaceutical ingredients or API’s.
Savile told Proactive Enterin recognized the need to employ more sustainable methods to manufacture its key development targets at reduced cost and less waste and sought Willow's expertise in developing and scaling biobased processes. The initial program will focus on the feasibility of developing a biobased pathway and, if successful, advance development toward implementation at commercial scale. The development phase of this funded collaboration is expected to last approximately three months. In 2024, the company aims to transition its research and development programs into commercial revenue, emphasizing the execution of commercial agreements, advancing technology, and expanding its innovator partnerships.
Savile underscored the goal of achieving these milestones without increasing overhead. The interview reflects Willow Biosciences' commitment to strategic growth and transformative solutions in the biotechnology sector. Stay tuned for more exciting developments from this innovative company led by Dr. Chris Savile, shaping the future of bioscience.